NextPharma Technologies Doubles Alu Alu Packaging Capacity at its Göttingen Cephalosporins Facility
Surrey, UK, 28th January 2009
NextPharma Technologies, a leading provider of pharmaceutical product development, contract manufacturing, cold chain and distribution outsourcing services, is pleased to announce that its Cephalosporins site in Göttingen, Germany has doubled its Alu Alu packaging capacity.
In response to increased demand for Alu Alu blister business NextPharma has increased its Cephalosporin packaging capacity to 18 million blisters per year - with the installation of a second flexible Alu/Alu blister-line which can also produce Alu/PVC/PVDC-blisters. This new machine provides currently nine different blisters Alu/Alu and Alu/PVC blisters sizes and 54 different blister formats, it also benefits from having the newest control units and a data matrix station for printing and saving pack serial numbers.
Dr Hermann Osterwald, Managing Director, Contract Manufacturing Services, NextPharma Technologies commented “This new machine which was installed at the end of last year will work well along side our existing Alu Alu blister line maximising packaging capacity and flexibility for our customers. Bill Wedlake, CEO, Nextpharma Technologies added – we’re aware of the rising requirement for this packaging technology and are pleased to be in a position to meet market demands’.
NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers including solids, liquids and semi-solid dosage forms, antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing (lyophilized and liquid fill), with particular expertise in product development and manufacture of oncology medicines.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry. We offer a full range of services from early phase product development, through clinical trial packaging to high volume commercial manufacturing. We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and narcotics. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
We operate globally with seven product development centres, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.
We have 1,200 employees dedicated to serving over 200 customers world wide and a customer base, which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies.
We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi- solids, liquids, sprays and dry dosage form technologies.
All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.